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OBJECTIVE— Diabetes, hypertension, dyslipidemia, obesity, nephrotoxicity of certain im-
munosuppressive drugs, and the persistence of a chronic alloimmune response may significantly
affect graft survival in end-stage renal disease (ESRD) type 1 diabetic patients who have under-
gone kidney transplant. The aim of this study was to ascertain the impact of kidney alone (KD)
or combined kidney-pancreas (KP) transplantation on renal energy metabolism.
RESEARCH DESIGN AND METHODS— We assessed high-energy phosphates
(HEPs) metabolism by using, in a cross-sectional fashion, 31P-magnetic resonance spectroscopy
in the graft of ESRD type 1 diabetic transplanted patients who received KD (n 20) or KP (n
20) transplant long before the appearance of overt chronic allograft nephropathy (CAN). Ten
nondiabetic microalbuminuric kidney transplanted patients and 10 nondiabetic kidney trans-
planted patients with overt CAN were chosen as controls subjects.
RESULTS— Simultaneous KP transplantation patients showed a higher -ATP/inorganic
phosphorus (Pi) ratio (marker of the graft energy status) versus the other groups, and a positive
correlation between -ATP/Pi phosphorus ratio and A1C was found. In the analysis limited to
the subgroup of normoalbuminuric patients, the difference in-ATP/Pi was still detectable in KP
patients compared with KD transplantation.
CONCLUSIONS— KP transplantation was associated with better HEPs than in KD trans-
plantation, suggesting that restoration of -cell function positively affects kidney graft
metabolism.
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In type 1 diabetic and end-stage renaldisease (ESRD) patients who haveundergone kidney alone (KD) trans-
plantation, diabetes, hypertension, dys-
lipidemia, obesity, nephrotoxicity of
certain immunosuppressors, and the per-
sistence of a chronic alloimmune re-
sponse may significantly affect graft
survival (1–3). Many of these factors can
induce glomerulosclerosis, tubular dam-
age, endothelial damage, and, ultimately,
deterioration of renal function leading to
the appearance of chronic allograft ne-
phropathy (CAN) of the transplanted kid-
ney (4).
Chronic allograft dysfunction is still
one of the major risk factors that affect
kidney survival, along with the death of
the functioning graft (5). No major break-
throughs have been proposed in the last
years, either in terms of early diagnosis or
as far as new treatments; only the correc-
tion of the associated disorders has been
pointed out (5). Other crucial points are
1) the earlier the diagnosis of renal dys-
function, the more successful is the treat-
ment and 2) the degree of invasiveness of
the approach is the other limiting factor.
Many authors strongly believe that
31P-magnetic resonance spectroscopy
(31P-MRS) can provide a potential solu-
tion for such an important issue (6–8).
Some previous articles (9,10) demon-
strated that CAN is accompanied by a de-
crease in -ATP/inorganic phosphorus
(Pi) ratio at 31P-MRS, and this was
thought to be the result of chronic isch-
emia of the kidney graft, which causes a
drop in ATP. In a recent study, Kazuhiko
et al. (10) have demonstrated that a kid-
ney -ATP/Pi ratio at 31P-MRS1.2 is an
independent risk factor for graft survival.
They discussed the role of -ATP/Pi ratio
as a parameter for predicting long-term
survival of a transplanted kidney, where a
value 1.2 suggests a high probability of
3-year renal survival and a value2.5 in-
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dicates that the transplanted kidney could
survive 5 years (10).
There are emerging data that restor-
ing -cell function associated with the
withdrawal of uremia in ESRD type 1 di-
abetes can prolong graft life compared
with withdrawal of uremia alone (11–13).
The aim of our study was to evaluate
whether metabolic markers of early kidney
dysfunction were noninvasively detectable
in vivo in the transplanted patients long be-
fore the appearance of overt CAN by using
31P-MRS. Furthermore, we evaluated
whether kidney-pancreas (KP) transplant
confers a protection on the kidney graft in
terms of high-energy phosphate (HEP)
metabolism, particularly at an early stage.
Finally, we used early markers of renal
hemodynamic changes to asses the ability
of 31P-MRS to detect early alterations of
kidney function (14,15).
RESEARCH DESIGN AND
METHODS
Patients and transplantation
Forty ESRD type 1 diabetic patients were
considered in our study and were en-
rolled in our waiting list for combined KP
transplantation. A first group of patients
underwent combined simultaneous KP
transplantation (n 20) from cadaver do-
nors. The second group underwent KD
transplantation (n  20) and comprised
either patients on the KP waiting list who
received a kidney and a pancreas from a
cadaver donor and who lost the pancreas
graft early in the postoperative period
(within 1–2 weeks, n  12) due to pan-
creas thrombosis or patients who under-
went renal transplantation only because
the pancreas showed macroscopic dam-
ages at harvesting (n 8). The two groups
are comparable for the most important
demographic characteristics upon enroll-
ment in the study (Table 1).
Ten nondiabetic ESRD patients who
received a kidney transplant and who ex-
perienced CAN (group REJ) and restarted
hemodialysis and 10 nondiabetic ESRD
patients who received kidney transplant
and have microalbuminuria were chosen
as controls for different degrees of renal
dysfunction.
Immunosuppression
Organs for transplantation were obtained
from cadaver donors through Nord Italia
Transplant. All patients received the fol-
lowing immunosuppressive treatments:
antithymoglobulin (IMTIX, SANGSTAT),
cyclosporine (blood trough levels be-
tween 100 and 250 ng/ml), FK506 (blood
levels between 10 and 15 ng/ml; only two
patients in the KP group and two in the
KD group were on FK506), mofetil myco-
phenolate (0.5–2 mg/day), and pred-
nisone (5–10 mg/day). Steroids were
tapered and then withdrawn within 6
months from time of transplant.
Study design and laboratory
assessment
For this study, only patients with trans-
plant follow-up 1 year were selected.
Only KP and KD transplantation patients
with good kidney graft function were in-
cluded in the study. Other than the usual
routine exams, urinary albumin excretion
(UAE) was assessed in an early-morning
spot urine sample (Albustix; Ames, Bayer
Diagnostic, Bayer, Germany). In Albustix-
positive samples, the urinary albumin
concentration was measured by immu-
nonephelometry with N albumin kits
(Behring, Somerville, NY). A ratio be-
tween 17 and 299 was defined as mi-
croalbuminuria, while higher values were
defined as overt macroalbuminuria.
Enzyme-linked immunosorbent
assay for urinary thromboxane B2
and 6-keto-prostaglandin-F-1
levels
At the time of 31P-MRS, we cross-
sectionally analyzed urinary thrombox-
ane B2 and 6-keto-prostaglandin-F-1
levels as markers of early deterioration of
glomerular function (16). Urinary levels
of 6-keto-prostaglandin-F-1 were as-
sayed with a correlate enzyme immu-
nosorbent assay kit (Assay Designs, Ann
Arbor, MI). Urinary levels of thrombox-
ane B2 were assayed with a correlate en-
zyme immunosorbent assay kit
31P-MRS protocol
Renal 31P-MRS was performed in the su-
pine position with the use of a 1.5T
whole-body scanner (Gyroscan Intera
Master 1.5 MR System; Philips Medical
Systems, Best, the Netherlands) as sug-
gested by Klemm et al. (6). 31P spectra
were obtained by means of a 10-cm diam-
eter surface coil used for transmission and
detection of radio frequency signals at the
resonance frequency of 31P (at 1.5 T,
Table 1—Pre- and posttransplant characteristics of ESRD type 1 diabetic patients who underwent KP or KD transplant
KP KD KA REJ
n 20 20 10 10
Age (years) 39.0  1.7 42.3  1.9 44.0  4.8 39.8  3.3
Diabetes duration (years)* 24.7  1.5 27.3  2.9 0 0
Dialysis duration (years) 2.7  0.5 3.1  0.5 4.0  1.3 2.3  0.6
Transplant follow-up (years)* 3.1  0.5 4.2  1.2 5.8  1.0 7.1  2.5
A1C (%)* 5.5  0.1 8.7  0.3 5.3  0.1 5.5  1.0
Fasting glucose levels (mg/dl)* 87.4  4.0 171.1  16.1 109.5  5.0 111.5  57.2
Cyclosporine trough levels (ng/ml) 176.2  25.8 181.7  10.1 165.5  18.5 NA
Total cholesterol (mg/dl) 175.5  10.5 178.7  12.5 189.0  16.0 161.6  22.5
Triglycerides (mg/dl)* 93.4  8.2 151.8  18.1 133.0  30.0 169.6  29.3
HDL (mg/dl)* 53.1  2.3 51.3  2.9 42.2  3.2 39.7  4.1
Smoking habits 3:20 2:20 2:10 2:10
Hypertension 8:20 11:20 3:10 10:10
Systolic blood pressure (mmHg)* 134.3  3.5 137.4  4.7 136.2  4.1 141.2  5.4
Diastolic blood pressure (mmHg)* 81.5  3.3 84.5  323 83.1  2.2 90.1  4.1
Data are means  SE or ratio. Two groups of patients with different renal function were chosen as controls (KA and REJ). *P  0.05 between groups.
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25.85 MHz). A small sample container
built in the coil center, containing an
aqueous solution of methyl-phospho-
nate, served as the geometrical reference.
Standard imaging was performed to ac-
quire scout images (SURVEY/BTFE) as
shown in Fig. 1A and B. Shimming was
performed with an automatic procedure
by optimizing the 1H-MR spectroscopy
water signal obtained with a volume-
selective 90°-180°-180° sequence. Shim
volumes were planned on the transverse
and sagittal scout images to include the
entire kidney, while avoiding skin, mus-
cles, and adipose tissue as much as possi-
ble. The transmitter receiver was then
switched without time delay to the 31P
frequency. Manual tuning and matching
of the 31P surface coil were performed to
adjust for different coil loading. The radio
frequency level was adjusted to obtain a
180° pulse of 40s for the reference sam-
ple at the center of the 31P surface coil.
ISIS volume selection in three dimensions
was the employed volume selection,
based on 192 averaged free induction de-
cays. The selection of the volume of inter-
est was planned from the transverse and
sagittal scout images and was oriented
perpendicular to the abdomen-pelvic
wall, avoiding inclusion of skin, adipose
tissue, and muscles. Acquisition time was
9 min 48 s. Examination time was 30 min.
31P-MR spectra were transferred to a
remote SUN-SPARC workstation for anal-
ysis. The spectra were quantified auto-
matically by model function analysis in
the time domain. Signals were obtained
also from phosphomonoesters, Pi, and
phosphodiesters. The spectral fitting rou-
tine was based on a nonlinear least-
squares Gauss-Newton implementation
for exponential damping (Fig. 1C). The
following parameters were obtained:
-ATP/Pi ratio (used as a marker of HEP
metabolism in vivo), phosphmonoester,
phosphodiester, -ATP, -ATP, and
-ATP (10).
Statistical analysis
All the data were expressed as means 
SD. When the three groups were com-
pared cross-sectionally, ANOVA with
Tukey’s test for multiple comparisons (for
parametric data) or a Kruskal-Wallis test
(for nonparametric data) was used ac-
cording to distribution. Correlations were
assessed with a Spearman’s rank correla-
tion coefficient. A P value0.05 (by two-
tailed testing) was considered an
indicator of statistical significance. Anal-
ysis of data were done using SPSS statis-
Figure 1—Magnetic resonance imaging of a transplanted kidney graft shows the position of the volume of interest used to obtain the 31P spectrum
for both axial (A) and sagittal (B) positions. 31P spectrum of a transplanted kidney (C). In the lower panel, the 31P spectrum shows resonance peaks
of phosphomonoesters (PME), Pi, phosphodiesters (PDE), and ATP. In the upper panel, the spectrum after line-fitting procedures is shown. FID, free
induction decays; ISIS, image-selective in vivo spectroscopy; TR, repetion time.
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tical package for windows (SPSS,
Chicago, IL).
RESULTS
Metabolic and clinical
characteristics and kidney function
Cardiovascular risk factors, including
age, total cholesterol, HDL, LDL, hyper-
tension, and smoking habits, were similar
in the two groups (Table 1). Triglyceride
levels were statistically lower in the KP
group compared with the KD and REJ
groups (Table 1, P 0.01). Patients in the
KP group showed, as expected, lower glu-
cose and A1C compared with the KD
group (Table 1, P  0.001). Patients in
the REJ group, as expected, showed al-
tered lipid metabolism and increased val-
ues of arterial blood pressure (Table 1).
No differences between the two
groups of transplanted patients were evi-
dent with regard to numbers of rejection,
HLA match, cold ischemia time, episodes
of cytomegalovirus infection, donor age,
BMI, and panel reactive antibodies pre-
transplant, and no infections or lympho-
proliferative diseases were evident in the
chosen patients (data not shown). Creat-
inine was 2 mg/dl in all patients in the
KP, KD, and microalbuminuric kidney
(KA) groups (Fig. 2A). UAE rates in all KP
and in almost all KD patients were within
the physiological range (Fig. 2B). How-
ever, the KD and KA groups showed
higher UAE levels compared with the KP
group (Fig. 2B). The REJ group exhibited
higher creatinine levels than the other
three groups (Fig. 2A), as well as frank
proteinuria in patients who still had the
ability to produce urine (data not shown).
-ATP/Pi ratio in the KP and KD
groups
-ATP/Pi ratio was higher in the KP group
compared with the KD group (P  0.05)
(Fig. 2C). The KP, but not KD, group had
a median 1.2, which indicates a proba-
bility of graft survival 5 years. We also
investigated eventual differences between
male and female donors and noticed that
KP and KD patients who received a kid-
ney graft from a female donor had a lower
-ATP/Pi ratio. This may be due to the
fact that women have a lower density of
nephrons and therefore a lower kidney
metabolism and kidney -ATP/Pi ratio.
We also researched a correlation be-
tween having a KD or a KP graft with a
Figure 2—Similar creatinine values were evident between the groups, except for those who experienced chronic rejection (REJ) (A). UAE is higher
in the nondiabetic microalbuminuric group (KA) and in the diabetic KD group, compared with the KP transplanted group (B). -ATP/Pi ratio is
higher in KP patients compared with KD, KA, or REJ patients (C). In the contest of normoalbuminuric patients, KP group showed higher -ATP/Pi
ratio compared with the KD group, suggesting an early alteration of this ratio before the appearance of microalbuminuria (D). REJ patients are those
with CAN.
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level of-ATP/Pi ratio1.2. The odds for
KD patients having -ATP/Pi ratio 1.2
are 3, while the odds of having -ATP/Pi
ratio 1.2 for KP patients are 0.5. The
REJ and KA groups showed statistically
lower -ATP/Pi ratios than the KP group
but not compared with the KD group. Fi-
nally, we could not find a correlation
between age and -ATP/Pi ratio (Spear-
man’s 	 
0.13, P  0.44).
Glucose metabolism and -ATP/Pi
ratio
Since nephropathy is the major complica-
tion of diabetes, we expect that patients
with residual diabetes (the KD group),
and therefore high levels of A1C (6%),
will have low levels of -ATP/Pi ratio and
thus will be predisposed for impaired re-
nal function compared with the KP
group. We tested whether there is a cor-
relation between levels of A1C and the
-ATP/Pi ratio. Results demonstrate an
inverse correlation between A1C levels
and -ATP/Pi ratio with a Spearman’s
	-correlation coefficient of 
0.40 and P
 0.03 (data not shown). It is important
to observe that our KD patients showed a
worse glycometabolic control, as shown
by high A1C (Table 1). This is not un-
usual, at least in our clinical experience,
and is most likely due to multiple factors
such as the use of diabetogenic medica-
tions (steroids and calcineurin inhibi-
tors), the presence of a single kidney, and
imperfect compliance to insulin therapy.
Finally, the early enrollment of KD pa-
tients in the islet transplantation waiting
list often makes the selection of these pa-
tients difficult.
Another important issue is the possi-
ble interference between hyperglycemia
per se and -ATP/Pi ratio. In this case, the
differences in the spectra could reflect
only the differences in degree of diabetes
control. We took advantage of a small co-
hort of patients who received islet trans-
plantation 1 year after the kidney
transplant. These patients (n 5) under-
went 31P-MRS during a phase of relatively
good glycometabolic control (A1C 6.9 
0.3%) due to a well-functioning islet
transplantation (all patients C-peptide
0.5 ng/ml). In this small group we still
detected an impaired -ATP/Pi ratio
(0.87 0.22) but was not statistically dif-
ferent from the KD group despite the dif-
ferent glucose control.
Microalbuminuria and -ATP/Pi
ratio and subanalysis in the
normoalbuminuric patients
The KA group, despite the absence of di-
abetes, showed a lower -ATP/Pi ratio
compared with the KP group, suggesting
that -ATP/Pi ratio is impaired in mi-
croalbuminuric patients and is a clear
marker of early kidney dysfunction. We
assessed the existence of a relationship
between UAE and -ATP/Pi ratio. A neg-
ative, although not statistically signifi-
cant, correlation was observed (data not
shown).
It is possible the altered HEP metab-
olism in the KD group is a consequence of
an incipient renal dysfunction, as sug-
gested by higher UAE in this group. We
decided to analyze the HEP metabolism in
the context of normoalbuminuric patients
of the two groups (KP and KD). Even in
this smaller cohort, a statistically signifi-
cant difference was evident in terms of
-ATP/Pi ratio between the two groups
(KP 1.78 0.40 vs. KD 0.92 0.12, P
0.02) (Fig. 2D).
Lipid metabolism and -ATP/Pi
ratio
It has been shown that augmented lipid
and lipoprotein levels increase the risk of
graft chronic rejection due to vascular
damage. Since cholesterol 190 mg/dl is
the major risk factor for atherosclerosis
and vascular complications, we investi-
gated the correlation between cholesterol
levels and -ATP/Pi ratio in our cohort of
patients. No significant correlation was
found with nonparametric Spearman’s
test (Spearman’s 	  
0.16, P  0.41).
Finally, we observed that levels of
triglycerides were different among the KP
and KD groups (P 0.01 for difference of
medians, Table 1). No significant correla-
tion was found with nonparametric
Spearman’s test (Spearman’s 	  0.21,
P  0.10).
Immunosuppressive treatment and
-ATP/Pi ratio
Calcineurin inhibitors have been seen to
have a dose-dependent cytotoxic effect on
the kidney; they can cause tubular dam-
age and vasospasm of the renal artery
(17,18). Alternatively to cyclosporine,
FK506 has been used for some patients,
although it has a similar pharmacological
action and a similar nephrotoxicity
(19,20). We therefore hypothesized that
high doses of an immunosuppressant
could correlate with low -ATP/Pi ratio.
In our samples, results demonstrate no
significant correlation (Spearman’s 	 

0.10, P 0.65) between doses of cyclo-
sporine and cyclosporine trough levels
and -ATP/Pi ratio (data not shown). The
same could be said for FK506, as there is
no significant correlation between dose
and -ATP/Pi ratio (data not shown).
Smoking and -ATP/Pi ratio
We did not detect any influences of smok-
ing on -ATP/Pi ratio (Spearman’s 	 
0.30, P  0.55). Our transplanted pa-
tients are aware of the potential negative
impact of smoking on their health condi-
tion, particularly in terms of cardiovascu-
lar problems and cancer progression.
Urinary thromboxane B2/6-keto-
prostaglandin-F-1 levels and -
ATP/Pi ratio
We evaluated urinary thromboxane B2
and 6-keto-prostaglandin-F-1 levels in
KP and KD groups as markers of early
deterioration of glomerular function (16).
It is particuarly known that in early stages
of diabetes, an elevation of glomerular fil-
tration rate is evident, with an increase in
urinary prostaglandins (16). These two
markers appeared to be augmented dur-
ing hyperfiltration and during the early
stages of diabetes or kidney disease. The
KP group showed nonstatistical lower
levels of urinary 6-keto-prostaglandin-
F-1 and urinary thromboxane B2 (data
not shown). Despite the small patient co-
hort, a negative trend was evident be-
tween urinary thromboxane B2 and
6-keto-prostaglandin-F-1 levels and
-ATP/Pi ratio (data not shown).
Sensitivity and specificity of kidney
spectroscopy
An estimate of intra-examination differ-
ences in -ATP/Pi was obtained in seven
transplanted subjects in which the spec-
troscopy scan was obtained twice in a
consecutive fashion on the same session
and without changing the position of the
surface coil, the sensitive volumes, and
the acquisition parameters. The coeffi-
cient of variation was 6 3%. Due to the
considerably smaller signal-to-noise ra-
tio, the variability was higher in the non-
diabetic kidney transplanted patients
with overt CAN (group REJ) (15  5%
tested in three patients).
CONCLUSIONS— Chronic allograft
dysfunction is one of the major problems
that transplanted patients face and still
represents one of the most important
causes of graft loss (2,5,21,22). Many fac-
Fiorina and Associates
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tors can detrimentally accelerate the bur-
den of CAN including hypertension,
dyslipidemia, overactive kidney, kidney
cold ischemia, and nephrotoxicity of cer-
tain drugs (5,23–27). It is particularly
well known that both calcineurin inhibi-
tors and rapamycin are nephrotoxic
(5,23–27), as they can induce tubular in-
jury and glomerular vasoconstriction,
leading to the worsening of kidney func-
tion (5,23–27). Most patients who expe-
rience CAN restart dialysis and ultimately
need retransplantation. The presence of
diabetes is, of course, another worsening
factor. We and others showed that restor-
ing -cell function, with either islet or
pancreas transplantation, can improve
graft survival (12,13,28). From a clinical
point of view, once the injury is estab-
lished, it is unlikely that the pathological
loop can be overturned; it is important to
discover more noninvasive tools to use at
the beginning of CAN in order to deter-
mine a propensity to develop chronic al-
lograft dysfunction.
Microalbuminuria, while it is an early
and noninvasive diagnostic tool, is also
sometimes nonspecific and difficult to
treat. In recent years, imaging techniques
showed great potential in studying meta-
bolic and vascular features of kidney
grafts (6,8,10,29,30). We and others re-
cently published (13,29) the use of Dopp-
ler imaging to evaluate intrarenal blood
flow, which joined kidney biopsy as a tool
to detect abnormalities in kidney vessel
morphology and functionality. MRS in
one of the most up-to-date tools to non-
invasively study organ metabolism
(6,8,10,29–31). In this work, we aimed
to use localized 31P-MRS to detect early
signs of kidney graft dysfunction before
the appearance of microalbuminuria and
to detect a possible early beneficial effect
of combined KP transplantation on kid-
ney graft metabolism.
In our study, 31P-MRS showed that
combined KP transplantation, compared
with KD transplantation, is associated
with a better HEP metabolism in the kid-
ney graft, using a cross-sectional ap-
proach. -ATP/Pi ratio appeared to be
correlated with A1C, suggesting a signifi-
cant effect of glycometabolic control on
HEP metabolism. Finally, these data were
confirmed even in normoalbuminuric pa-
tients when there are no evidences of kid-
ney dysfunction.
Pancreas cotransplantation can halt
the progression of diabetic nephropathy
in KP patients ameliorating HEP metabo-
lism, thereby improving the survival of
the kidney graft, ameliorating vascular
function, and preventing the reduction of
renal functional reserve (4,11,32). 31P-
MRS can be helpful for detecting early
dysfunction of the kidney graft long be-
fore the appearance of an overt disease.
We would like to call attention to the fact
that among the measured parameters, an
impairment of-ATP/Pi ratio is the first to
appear even in normoalbuminuric pa-
tients. While creatinine levels and albu-
min excretion rate are normal in all
patients, -ATP/Pi ratio is lower in pa-
tients with type 1 diabetes after KD trans-
plantation than in patients with type 1
diabetes after KP transplantation.
The utility of -ATP/Pi ratio as a
marker of renal dysfunction is evidenced
by comparing control groups with differ-
ent degrees of kidney dysfunction (33).
From normoalbuminuric (KP group) to
microalbuminuric (KA or, to a lesser ex-
tent, KD group) to frank proteinuric (REJ
group) patients, a progressive worsening
of -ATP/Pi ratio is evident. We analyzed
early markers of renal hemodynamics
such as urinary thromboxane B2 and
6-keto-prostaglandin-F-1. Both are in-
creased in type 1 diabetic patients and
in other kidney diseases during the early
hyperfiltration phase. KD patients
showed increased levels of both urinary
markers, suggesting that they are hyper-
filtrating. Interestingly, in diabetic patients,
-ATP/Pi ratio showed a negative correla-
tion, though not statistically significant,
with urinary thromboxane B2 and 6-keto-
prostaglandin-F-1.
Glucose control does not seem to al-
ter, at least acutely, HEP metabolism, as
shown by the analysis of kidney-islet
transplanted patients. Despite lower gly-
cemia, they still showed altered HEP
metabolism.
Limitations of the study
The major limitation of this study is the
use of a cross-sectional study, although
the two populations were homogeneous
before transplantation. -ATP/Pi ratio of
kidney graft was not specifically studied
at the moment of transplant, and we can-
not completely exclude the presence of
some unstudied biases. Furthermore, we
acknowledge the complexity of the pro-
cedure and the lack of extensive studies
addressing the specificity and sensibility
of the procedures.
Our study shows a higher ratio of
-ATP/Pi in ESRD type 1 diabetic patients
who underwent KP transplant compared
with those who underwent KD trans-
plant. This could have direct conse-
quences on the prognosis of the graft if we
believe that an altered HEP metabolism is
the sign of early kidney graft dysfunction.
These data confirm that KP transplanta-
tion is protective (compared with KD
transplantation) for chronic rejection or
for recurrence of diabetic nephropathy
as previously suggested by others
(12,13,28,34). Furthermore, we demon-
strated for the first time that even in the
absence of an overt renal dysfunction (as
suggested, for example, by increased cre-
atinine levels or by the appearance of pro-
teinuria), the kidney graft showed early
markers of impairment that could be used
as a target for therapy. Our data con-
firmed the body of evidence that restora-
tion of -cell function is helpful for the
kidney graft with important metabolic ef-
fects. The importance of our findings has
to be validated with longitudinal studies
addressing particularly the sensibility of
31P-MRS in predicting graft dysfunction.
Only such an approach will confirm the
real value of 31P-MRS as a useful clinical
technique.
Acknowledgments— We are grateful to Mol-
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